RECRUITINGPhase 4INTERVENTIONAL
Use of CXCL9 as a Biomarker of Acthar Efficacy
About This Trial
The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).
Who May Be Eligible (Plain English)
Who May Qualify:
- Biopsy-proven diagnosis of sarcoidosis with demonstrated pulmonary involvement
- Refractoriness to or intolerance of immunosuppressive agents like prednisone or methotrexate
Who Should NOT Join This Trial:
- Smoking
- Cancer
- Chronic infections (e.g. tuberculosis, viral, fungal, bacterial)
- Inflammatory conditions
- Coexisting lung disease
- Congestive heart failure
- Uncontrolled hypertension
- Recent surgery
- Active peptic ulcers
- Osteoporosis
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Biopsy-proven diagnosis of sarcoidosis with demonstrated pulmonary involvement
* Refractoriness to or intolerance of immunosuppressive agents like prednisone or methotrexate
Exclusion Criteria:
* Smoking
* Cancer
* Chronic infections (e.g. tuberculosis, viral, fungal, bacterial)
* Inflammatory conditions
* Coexisting lung disease
* Congestive heart failure
* Uncontrolled hypertension
* Recent surgery
* Active peptic ulcers
* Osteoporosis
Treatments Being Tested
DRUG
Acthar gel
Acthar gel given IM or SQ as per package insert
Locations (1)
University of California, San Francisco
San Francisco, California, United States